GlaxoSmithKline reports positive clinical data for Nucala

GlaxoSmithKline has announced new clinical trial data showing the benefits of Nucala, its new biologic therapy for asthma patients.

The phase IIIb MUSCA study was able to successfully meet all of its primary and secondary endpoints after delivering significant improvements for severe asthma patients whose disease was driven by eosinophilic inflammation.

Nucala, when used in conjunction with the current standard of care, was associated with key improvements in health-related quality of life and lung function when compared to patients treated with placebo and standard of care.

Dr Frank Albers, medical affairs lead for Nucala at GlaxoSmithKline, said: "By demonstrating improvements in a range of important markers of asthma control, including quality of life and lung function, this data reinforces the valuable role Nucala can play in the treatment of some of the most severe asthma patients."

Individuals affected by this condition currently have limited treatment available to them, with shortness of breath, wheezing, coughing and asthma attacks representing the most common and debilitating symptoms.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.